3,4-dihydroxyphenylacetic acid has been researched along with rotenone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Wesemann, W | 1 |
| Cano, J; Granero, L; Machado, A; Santiago, M | 1 |
| Eisenhofer, G; Harvey-White, J; Hayakawa, Y; Kirk, K; Kopin, IJ; Lamensdorf, I | 1 |
| Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A | 1 |
| Di Monte, DA; Langston, JW; Thiffault, C | 1 |
| Brown, AM; Burke, WJ; Conway, AD; Jain, JC; Kristal, BS; Li, SW; Ulluci, PA | 1 |
| Antkiewicz-Michaluk, L; Bojarski, AJ; Karolewicz, B; Michaluk, J; Romańska, I; Vetulani, J | 1 |
| Crutchfield, KC; Dluzen, DE | 1 |
| Cavada, C; Cuadrado, A; de Sagarra, MR; Rojo, AI | 1 |
| Aoki, E; Araki, T; Kato, H; Kimoto, H; Yano, R; Yokoyama, H | 1 |
| Nehru, B; Thakur, P | 1 |
| Cooney, A; Goldstein, DS; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Batool, Z; Haider, S; Liaquat, L; Madiha, S; Perveen, T; Sadir, S; Shahzad, S; Tabassum, S | 1 |
| Haider, S; Madiha, S | 1 |
| Bhurtel, S; Choi, DY; Katila, N; Neupane, S; Srivastav, S | 1 |
| Chen, J; Hu, H; Li, LX; Liu, CF; Lv, DJ; Wang, F; Wei, SZ; Xie, AM | 1 |
| Feng, Y; Ma, J; Yuan, L | 1 |
| Goldstein, DS; Halperin, R; Landau, R; Leibowitz, A; Sharabi, Y; Sullivan, P; Zibly, Z | 1 |
20 other study(ies) available for 3,4-dihydroxyphenylacetic acid and rotenone
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Electrochemistry; Free Radicals; Haloperidol; Hydroxyindoleacetic Acid; Male; Memantine; Neurotoxins; Parkinson Disease; Rats; Rats, Wistar; Rotenone; Serotonin; Substantia Nigra | 1992 |
Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Microdialysis; Nomifensine; Rats; Rats, Wistar; Rotenone; Substantia Nigra; Uncoupling Agents | 1995 |
Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Line; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Electron Transport; Glucose; Homovanillic Acid; Humans; L-Lactate Dehydrogenase; Mitochondria; Nerve Growth Factor; Neurons; Neurotoxins; Oxidation-Reduction; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone; Stress, Physiological; Uncoupling Agents | 2000 |
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy Metabolism; Enzyme Inhibitors; Estrogens, Non-Steroidal; Fluorenes; Hydantoins; Isoflavones; Mitochondria; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone | 2000 |
Increased striatal dopamine turnover following acute administration of rotenone to mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chelating Agents; Corpus Striatum; Ditiocarb; Dopamine; Dopamine Agents; Homovanillic Acid; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Rotenone; Uncoupling Agents | 2000 |
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Cell Death; Cell Differentiation; Cyclosporine; Dopamine; Dopamine Antagonists; Enzyme Inhibitors; Ion Channels; Male; Membrane Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nerve Growth Factor; para-Aminobenzoates; Parkinson Disease; PC12 Cells; Phenanthrenes; Rats; Rats, Inbred F344; Respiration; Rotenone; Trifluoperazine; Uncoupling Agents | 2001 |
1-methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Brain; Corpus Striatum; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Homovanillic Acid; Insecticides; Isoquinolines; Male; Nucleus Accumbens; Rats; Rats, Wistar; Rotenone; Substantia Nigra; Survival Rate; Tetrahydroisoquinolines | 2003 |
Rotenone produces opposite effects upon mouse striatal dopamine function as a result of environmental temperature.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Insecticides; Methamphetamine; Mice; Rotenone; Temperature | 2006 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhalation; Administration, Intranasal; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Herbicides; Insecticides; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Degeneration; Neurons; Paraquat; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra | 2007 |
Chronic administration with rotenone does not enhance MPTP neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuropsychological Tests; Rotenone; Uncoupling Agents | 2010 |
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Catalase; Cytokines; Dopamine; Homovanillic Acid; Inflammation; Male; Monoamine Oxidase; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rotenone; Sodium Salicylate | 2013 |
Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Dopamine; Electron Transport Complex I; Glioblastoma; Glioma; Humans; NAD; Parkinson Disease, Secondary; PC12 Cells; Rats; Rotenone; Uncoupling Agents | 2015 |
Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dopamine; Gait; Male; Motor Activity; Muscle Weakness; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone | 2017 |
Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Choice Behavior; Corpus Striatum; Curcumin; Depression; Disease Models, Animal; Dopamine; Hippocampus; Hydroxyindoleacetic Acid; Neuronal Plasticity; Neuroprotective Agents; Rats; Rats, Wistar; Rotenone; Serotonin; Social Behavior | 2019 |
Mechanistic comparison between MPTP and rotenone neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Brain; Dopamine; Male; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Parkinsonian Disorders; Rotenone | 2019 |
Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cognition; Disease Models, Animal; Dopamine; Emotions; Male; Memory; Motor Activity; Parkinson Disease; Rotenone; Sleep Deprivation; Zebrafish | 2019 |
β-Methylphenylalanine exerts neuroprotective effects in a Parkinson's disease model by protecting against tyrosine hydroxylase depletion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aminobutyrates; Animals; Cell Survival; Dopamine; Humans; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Neuroprotective Agents; Parkinson Disease; Rats; Reactive Oxygen Species; RNA, Messenger; Rotenone; Tyrosine 3-Monooxygenase | 2020 |
The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamines; Dopamine; Parkinson Disease; Rats; Rotenone | 2022 |